Skip to content

Technical Development of Xe MRI

Technical Development of Xe MRI in Children and Adults

Status
Enrolling by invitation
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07823010
Enrollment
550
Registered
2026-09-16
Start date
2024-01-01
Completion date
2030-01-01
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HSCT, Lung Transplant Recipient

Brief summary

The goal of this study is to develop and optimize new proton (1H; conventional MRI) and Xe gas MRI techniques to assess regional cardiopulmonary structure and function in the clinical setting. Specifically, three forms of Xe MRI techniques will be our focus: (1) imaging of the Xe ventilation distribution (which is the current FDA-approved indication for Xe MRI); (2) imaging the alveolar microstructure via the Xe apparent diffusion coefficient (ADC); and (3) detecting via spectroscopy and imaging Xe gas dissolved in the pulmonary blood and tissues upon inhalation.

Interventions

The total dosing volume will be consistent with CCHMC Department of Radiology clinical standards or up to 1/6th of a participant's total lung capacity (calculated or predicted from ATS guidelines or from participant's plethysmography data if available within 6 months of MRI scan) for participants under 18 years old and 1000 milliliters for adults. No more than a total of five Xe gas doses, combined clinical and research doses, will be administered during the scanning session.

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Participant is having a clinically-ordered hyperpolarized Xe gas MRI scan

Exclusion criteria

* Pregnancy or positive pregnancy test * Standard MRI exclusions

Design outcomes

Primary

MeasureTime frameDescription
Xenon gas Defect Distribution Index (DDI)Through study completion, an average of 5 yearsThe signal intensity of Xe gas in a voxel (in arbitrary units) as compared to neighboring voxels, with a higher DDI indicating more clustered and focal Xe defects.

Secondary

MeasureTime frameDescription
Apparent-Diffusion Coefficient (ADC) of Xe gas within the alveolar airspace.Through study completion, an average of 5 yearsMeasurement of the Xe apparent-diffusion coefficient (ADC), in units of cm\^2/s, with a larger value indicating more airspace dilation.
Xenon RBC:Membrane ratioThrough study completion, an average of 5 yearsThe ratio of Xe signal intensity (in arbitrary units) within the red-blood cell (RBC) compartment and membrane (interstitial tissue) compartments of pulmonary diffusion measured during dissolved-phase Xe MRI.
Xe gas time constantThrough study completion, an average of 5 yearsThe rate at which Xe gas signal intensity changes during dynamic images, in arbitrary units/second.
Length in time of Xe MRI acquisitionThrough study completion, an average of 5 yearsMeasurement of time in seconds for the duration of the Xe MRI acquisition.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026